Indianapolis, IN – Eli Lilly has announced that starter doses of the weight-loss drug Zepbound are now available in single-dose vials, aiming to enhance supply in response to high demand. The drug manufacturer has opted for a new method, with patients now using syringes instead of preloaded injector pens to administer the medication.
Tirzepatide, the active ingredient in Zepbound and Mounjaro, belongs to a new class of medications for obesity and diabetes that have surged in popularity, causing shortages and leading some individuals to turn to compounded versions made by pharmacies. The release of these new vials is expected to meet the growing demand for obesity medicine and provide more accessible treatment options for patients, according to Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA.
These single-dose vials will be exclusively available for out-of-pocket purchases through LillyDirect, a platform that offers telehealth services and assists patients with prescription refills. Priced at $399 for a four-week supply of 2.5-milligram vials and $529 for a four-week supply of 5-milligram vials, these costs are significantly lower than other GLP-1 medicines for obesity.
In a statement, President Joe Biden commended Eli Lilly for taking steps to lower drug prices by offering a direct-to-consumer version of their medication at a reduced cost. The President emphasized the importance of drug companies reducing prices across the board to make essential medications more affordable for American families.
Tirzepatide mimics hormones that boost insulin release, increase feelings of fullness, and reduce appetite by targeting GIP and GLP-1 hormone receptors. Concerns have been raised about the availability of compounded versions of these drugs, prompting warnings from the FDA regarding potential risks associated with dosing errors and safety concerns.
Dr. Jody Dushay, an endocrinologist, highlighted the flexibility in doses that the syringe and vial format allows, offering personalized treatment options for patients. Clinical trial data suggests significant weight loss benefits for individuals using tirzepatide injections. Additionally, recent studies have shown that tirzepatide is more effective in promoting weight loss compared to other medications in its class.
The move by Eli Lilly to make starter doses of Zepbound available in single-dose vials marks a significant step towards expanding access to safe and effective treatment options for individuals battling obesity and diabetes.